How does CBG compare to CBD?
Comparatively to CBD, there is signifi cantly fewer research
available on CBG. But if it piques your interest, we have
listed below some examples of what has been discovered
about this teenage cannabinoid so far:
In 2013, researchers concluded that CBG may have a
positive effect on patients with irritable bowel disease
(IBD). In this case, Colitis was induced using a murine
model.
in treating Methicillin-Resistant-Staphylococcus
– Aureus (MRSA) as Vancomycin, which is widely
regarded as one of the last drugs left in the treatment
of antibiotic resistance. It’s not clear what the other
four cannabis compounds were.
The cannabinoid appeared to successfully kill common
MRSA microbes and cells which drive repeat infections.
It also removed hard to clear biof ilms of MRSA that
form on skin and implants.
In pre-clinical studies, a pharmaceutical company recently
announced their preliminary studies have shown an anti-
tumour effect on the human stomach and bone cancer
cell lines, using CBG.
Little is known about the circumstances of this trial.
According to McMaster University in Canada, CBG could
be vital in the fi ght against the development of antibiotic
resistant super strains of common infections, also known
as ‘superbugs’.
In the study, which was not published in full before this
issue went to print, researchers screened fi ve cannabis
compounds for their antibiotic properties in the fi ght to
combat the rise of antibiotic resistance.
Out of the fi ve compounds, CBG was proven as successful
Eric Brown, a microbiologist who led the work at
McMaster University in Ontario, said that cannabinoids
were “clearly great drug-like compounds” but noted
the compounds would need to be assessed for use in
clinics.
“There is much work to do to explore the potential of
cannabinoids as antibiotics f rom the safety standpoint,”
he said.
Elsewhere, a study where CBG was tested for appetite
stimulation effects in mice, the feed rate was found to
have signif icantly increased, which may prove useful as
a for treatment in eating disorders in years to come.
Dr Richard’s bio:
Dr Richard Cunningham has a PhD in medicinal chemistry f rom Queen’s University Belfast, where he also worked as a post-doctoral researcher. Dr
Cunningham has also worked as a research instructor at the University of South Alabama’s Mitchell Cancer Institute. Among his areas of expertise are
organic synthesis, nucleosides, nucleotides, cellular biology, vitamins, aminoglycosides, drug delivery, phosphorous chemistry and chemical analysis.
43